Alternative splicing and residual function potentially expand the therapeutic landscape of the CFTRdele2ins182 variant
PLOS One · 2025
DOI: 10.1371/journal.pone.0330974 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Cristina Pastorino und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Alternative Splicing, Cystic Fibrosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione per la Ricerca sulla Fibrosi Cistica, Ministero della Salute.
Abstract (Originalsprache)
This study investigates the molecular and functional consequences of rare CFTR variants, particularly focusing on the complex allele [186-13C > G; 1898 + 3A > G] and the CFTRdele2ins182 rearrangement. Using patient-derived nasal epithelial cells, the research characterized the transcripts produced by these variants, revealing that CFTRdele2ins182, previously considered a null allele, generates alternative mRNA isoforms, one of which potentially encodes a partially functional CFTR protein. Functional assays in both heterologous and patient-derived cell models explored the impact of CFTR modulators on these variant proteins. While some rescue of CFTR activity was observed with specific modulator combinations in certain variants, the study highlights the complexity of genotype-phenotype correlations in CF and emphasizes the importance of personalized functional characterization of rare CFTR variants to guide therapeutic strategies. The findings suggest that even variants thought to be null alleles may produce proteins with residual function, opening avenues for developing targeted therapies for a broader range of CF patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
- Department of Neurosciences, rehabilitation, Ophthalmology; Genetics and Maternal and Child Sciences (DINOGMI), University of Genoa, Genoa, Italy.
- Department of Pediatric Medicine, Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Centre, Florence, Italy.
- Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
- Cystic Fibrosis Center, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
ORCID-Profile: Francesco Blasi, Nicoletta Pedemonte
Förderung
- Fondazione per la Ricerca sulla Fibrosi Cistica
- Ministero della Salute
Zitieren
APA
Pastorino, C., Menta, L., Pesce, E., Lena, M., Tomati, V., Capurro, V., Di Duca, M., Terlizzi, V., Gramegna, A., Blasi, F., Castellani, C., Cappato, S., Zara, F., Pedemonte, N., & Bocciardi, R. (2025). Alternative splicing and residual function potentially expand the therapeutic landscape of the CFTRdele2ins182 variant. PLOS One. https://doi.org/10.1371/journal.pone.0330974
Vancouver
Pastorino C, Menta L, Pesce E, Lena M, Tomati V, Capurro V, et al. Alternative splicing and residual function potentially expand the therapeutic landscape of the CFTRdele2ins182 variant. PLOS One. 2025. doi:10.1371/journal.pone.0330974
BibTeX
@article{Pastorino2025,
author = {Pastorino, Cristina and Menta, Ludovica and Pesce, Emanuela and Lena, Mariateresa and Tomati, Valeria and Capurro, Valeria and Di Duca, Marco and Terlizzi, Vito and Gramegna, Andrea and Blasi, Francesco and Castellani, Carlo and Cappato, Serena and Zara, Federico and Pedemonte, Nicoletta and Bocciardi, Renata},
title = {Alternative splicing and residual function potentially expand the therapeutic landscape of the CFTRdele2ins182 variant},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0330974}
}
EUVIMED